Second Quarter 2023 Earnings Call Call Agenda Welcome Jessica Tieszen | Associate Director, Investor Relations CEO Opening Remarks Steve Davis | Chief Executive Officer Commercial Update Brendan Teehan | Chief Operating Officer, Head of Commercial R&D Update Doug Williamson, M.D. | Head of Research and Development Financial Update Mark Schneyer | Chief Financial Officer Closing Remarks Steve Davis | Chief Executive Officer Kathie Bishop, Ph.D. | Chief Scientific Officer, Head of Rare Disease, available for ...